{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T19:34:27Z","timestamp":1785180867305,"version":"3.55.0"},"reference-count":16,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,2,8]],"date-time":"2017-02-08T00:00:00Z","timestamp":1486512000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","lungcancerjournal.info","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1016\/j.lungcan.2017.02.005","type":"journal-article","created":{"date-parts":[[2017,2,9]],"date-time":"2017-02-09T15:45:30Z","timestamp":1486655130000},"page":"110-114","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":63,"special_numbering":"C","title":["Dual occurrence of ALK G1202R solvent front mutation and small cell lung cancer transformation as resistance mechanisms to second generation ALK inhibitors without prior exposure to crizotinib. Pitfall of solely relying on liquid re-biopsy?"],"prefix":"10.1016","volume":"106","author":[{"given":"Sai-Hong Ignatius","family":"Ou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas K.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Y.","family":"Fernandez-Rocha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dean","family":"Pavlick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexa B.","family":"Schrock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viola W.","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Milliken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siraj M.","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara J.","family":"Gitlitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lungcan.2017.02.005_bib0005","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1097\/JTO.0000000000000094","article-title":"Next-generation sequencing reveals a novel NSCLC ALK. F1174 V mutation and confirms ALK G1202R mutation confers high-level resistance to alectinib (CH5424802\/RO5424802) in ALK-rearranged NSCLC patients who progressed on crizotinib","volume":"9","author":"Ou","year":"2014","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2017.02.005_bib0010","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1158\/2159-8290.CD-13-0846","article-title":"The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer","volume":"4","author":"Friboulet","year":"2014","journal-title":"Cancer Discov."},{"key":"10.1016\/j.lungcan.2017.02.005_bib0015","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1158\/2159-8290.CD-16-0596","article-title":"Molecular mechanisms of resistance to first- and second-generation ALK inhibitors in ALK-rearranged lung cancer","volume":"6","author":"Gainor","year":"2016","journal-title":"Cancer Discov."},{"key":"10.1016\/j.lungcan.2017.02.005_bib0020","doi-asserted-by":"crossref","first-page":"e55","DOI":"10.1016\/j.jtho.2015.12.097","article-title":"A case of ALK-rearranged adenocarcinoma with small cell carcinoma-like transformation and resistance to crizotinib","volume":"11","author":"Cha","year":"2016","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2017.02.005_bib0025","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1093\/annonc\/mdw032","article-title":"Transformation of ALK rearrangement-positive adenocarcinoma to small-cell lung cancer in association with acquired resistance to alectinib","volume":"27","author":"Takegawa","year":"2016","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.lungcan.2017.02.005_bib0030","doi-asserted-by":"crossref","first-page":"e67","DOI":"10.1016\/j.jtho.2015.12.105","article-title":"Transformation to SCLC after treatment with the ALK inhibitor alectinib","volume":"11","author":"Fujita","year":"2016","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2017.02.005_bib0035","first-page":"170","article-title":"Transformation to small-cell lung cancer as a mechanism of acquired resistance to crizotinib and alectinib","volume":"46","author":"Miyamoto","year":"2016","journal-title":"Jpn. J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2017.02.005_bib0040","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.lungcan.2015.12.001","article-title":"Neuroendocrine phenotype as an acquired resistance mechanism in ALK-rearranged lung adenocarcinoma","volume":"92","author":"Caumont","year":"2016","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2017.02.005_bib0045","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.lungcan.2016.10.012","article-title":"Histological transformation of ALK rearranged adenocarcinoma into small cell lung cancer: a new mechanism of resistance to ALK inhibitors","volume":"102","author":"Levacq","year":"2016","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2017.02.005_bib0050","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.ccell.2015.05.010","article-title":"PF-06463922, an ALK\/ROS1 inhibitor, overcomes resistance to first and second generation ALK inhibitors in preclinical models","volume":"28","author":"Zou","year":"2015","journal-title":"Cancer Cell"},{"key":"10.1016\/j.lungcan.2017.02.005_bib0055","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.jtho.2016.09.119","article-title":"Emergence of preexisting MET Y1230C mutation as a resistance mechanism to crizotinib in NSCLC with MET exon 14 skipping","volume":"12","author":"Ou","year":"2017","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2017.02.005_bib0060","doi-asserted-by":"crossref","first-page":"e39","DOI":"10.1097\/JTO.0b013e3182762bcb","article-title":"First case of combined small-cell lung cancer with adenocarcinoma harboring EML4-ALK fusion and an exon 19 EGFR mutation in each histological component","volume":"7","author":"Toyokawa","year":"2012","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2017.02.005_bib0065","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.lungcan.2013.05.022","article-title":"An extremely rare case of small-cell lung cancer harboring variant 2 of the EML4-ALK fusion gene","volume":"81","author":"Toyokawa","year":"2013","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2017.02.005_bib0070","doi-asserted-by":"crossref","first-page":"e165","DOI":"10.1016\/S1470-2045(14)71180-5","article-title":"Transformation from non-small-cell lung cancer to small-cell lung cancer: molecular drivers and cells of origin","volume":"16","author":"Oser","year":"2015","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.lungcan.2017.02.005_bib0075","doi-asserted-by":"crossref","first-page":"6922","DOI":"10.1073\/pnas.87.17.6922","article-title":"A single amino acid substitution results in a retinoblastoma protein defective in phosphorylation and oncoprotein binding","volume":"87","author":"Kaye","year":"1990","journal-title":"Proc. Nat. Acad. Sci."},{"key":"10.1016\/j.lungcan.2017.02.005_bib0080","doi-asserted-by":"crossref","unstructured":"L. Horn, H. Wakelee, K. Reckamp, et al., A Phase I\/II trial of ensartinib+ (X-396) in patients with alk fusion+ non-small cell lung cancer (NSCLC): Correlation with plasma and tissue genotyping and response to therapy. European Society of Medical Oncology (ESMO) 2016 Annual meeting (Copenhagen, Denmark). Abstract#3636.","DOI":"10.1093\/annonc\/mdw383.10"}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500217300375?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500217300375?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,18]],"date-time":"2019-09-18T09:48:58Z","timestamp":1568800138000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500217300375"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4]]},"references-count":16,"alternative-id":["S0169500217300375"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2017.02.005","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2017,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dual occurrence of ALK G1202R solvent front mutation and small cell lung cancer transformation as resistance mechanisms to second generation ALK inhibitors without prior exposure to crizotinib. Pitfall of solely relying on liquid re-biopsy?","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2017.02.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 The Author(s). Published by Elsevier Ireland Ltd.","name":"copyright","label":"Copyright"}]}}